Redmile & Scholar Rock: A Perfectly Annoying Situation

by

So, Redmile Group—these guys—they decided to buy a whole lot more shares of Scholar Rock. 1,316,390, to be exact. Forty-nine-point-three-seven million dollars worth. It’s just…a commitment, you know? Like when you accidentally agree to host Thanksgiving and then realize you don’t even like your relatives. It’s that level of dedication to something potentially…irritating. February 17th, 2026, they filed it. Like it needed to be documented. As if anyone cares about the precise date of a large stock purchase.

What’s the Deal?

Apparently, this Redmile group—they’re increasing their position in Scholar Rock. By a lot. $49.37 million. And the value of their existing shares also went up $84.58 million. It’s just…excessive. Like ordering a side of guacamole when you already know you’re going to spill it on your shirt. It’s tempting fate. And then they expect gratitude? For throwing money at a biotech company?

More to Know (Because Apparently, We Need More Details)

  • Redmile now owns 16.94% of Scholar Rock. 16.94%! It’s not a majority stake. It’s just…enough to be annoying. Like having a neighbor who almost waves back.
  • Here’s what they’re holding, because we need to quantify everything:
    • NASDAQ:SRRK: $229.98 million (16.9% of AUM)
    • NASDAQ:KRYS: $167.08 million (12.3% of AUM)
    • NASDAQ:NRIX: $153.54 million (11.3% of AUM)
    • NASDAQ:STOK: $128.04 million (9.4% of AUM)
    • NASDAQ:IMNM: $122.83 million (9.0% of AUM)

    It’s like a meticulously curated collection of…risk.

  • As of February 17th, Scholar Rock shares were up 25.7% over the past year. Beating the S&P 500 by 13.39 percentage points. Fine. Good for them. But does that mean I have to hear about it?

The Company, If You Must Know

Metric Value
Price (as of market close 2026-02-17) $46.45
Market Capitalization $4.78 billion
Net Income (TTM) $-353.43 million
One-Year Price Change 25.71%

What Scholar Rock Actually Does (Brace Yourself)

  • They develop biopharmaceutical products. For serious diseases. Like that’s supposed to impress me.
  • They focus on protein growth factor inhibitors. I have no idea what that means, and frankly, I don’t want to know.
  • They treat neuromuscular disorders, cancer, and fibrotic diseases. Sounds… exhausting.

So, Scholar Rock is a biotech company. They’re trying to figure out how to fix things that are broken. Which, honestly, is a full-time job. They have a “proprietary platform.” Everyone has a proprietary platform. It’s the buzzword of the decade.

What This All Means (If Anything)

This Redmile purchase? It’s a statement. A statement that says, “We’re willing to gamble on something that could easily go sideways.” It’s like ordering the fish at a diner you know is questionable. Scholar Rock plans to resubmit an application for a drug for spinal muscular atrophy. They have $365 million in cash. Good for them. But all this concentration in clinical-stage companies? It’s reckless. 17% of their assets are tied up in one biotech firm. That’s not diversification, that’s…optimism bordering on delusion. Shares are up, yes, but the market is already factoring in potential progress. They have other programs in development. More potential for…disappointment. It’s a whole system built on hope and very little actual certainty. It’s just… a lot.

Read More

2026-02-22 20:42